Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Dermatologic 3

Conditions

Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Skin Neoplasms 2Lymphoma 2Melanoma 1Lymphoma, T-Cell 1Kidney Neoplasms 1

Interventions

Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 43fludarabine phosphate 42Mycophenolic Acid 30Whole-Body Irradiation 27Cyclosporine 27Busulfan 26Tacrolimus 23Antilymphocyte Serum 23Methotrexate 20Etoposide 20romidepsin 19Filgrastim 19Melphalan 16Radiotherapy 15Flow Cytometry 15Vorinostat 13Methylprednisolone 13Brentuximab Vedotin 13Lenalidomide 12Bexarotene 12mogamulizumab 11Psychiatric Rehabilitation 11Bortezomib 11Therapeutics 10Rituximab 10Gemcitabine 10fludarabine 9Polymerase Chain Reaction 9Biopsy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, T-Cell, Cutaneous × zanolimumab × Clear all
NCT00071071 2023-05-18

Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
25 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00071084 2023-04-28

Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.

Genmab

Phase 2 Completed
22 enrolled
DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Skin Neoplasms, Lymphoma, T-Cell, Cutaneous

NCT00127881 2012-07-26

Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome

Emergent Product Development Seattle LLC

Phase 3 Terminated
76 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡